NEW YORK CITY -- It was increasingly clear that clinical trials alone won't tell the full story of how transcatheter aortic valve replacement (TAVR) performs in the real world, according to midterm studies presented here.
In a 7-year report of PARTNER 3 -- in which low-risk patients with symptomatic severe aortic stenosis were randomized to TAVR with the Sapien 3 valve or surgery -- the two groups showed comparable and sustained valve durability, with low and similar rates of structural valve deterioration and bioprosthetic valve failure (BVF).
In particular, there were favorable results in the proportion of patients alive and free of all-cause BVF (73.4% with TAVR vs 74.8% with surgery, P=0.69) and the rate of valve reintervention (6.0% vs 5.5%, P=0.77) in the trial, reported Philippe Pibarot, DVM, PhD, of the Institut Universitaire de Cardiologie et de Pneumologie de Québec.
This analysis of PARTNER 3 was presented at the New York Valves annual conference hosted by the Cardiovascular Research Foundation, and was simultaneously published in JAMA Cardiology.
However, it was a different story when it came to real-world TAVR outcomes.
